GLP-1 medications can make it easier to eat less, but weight loss still depends on maintaining a calorie deficit over time
although NAION events were rare among GLP-1 receptor agonist users, the possibility of small risk differences, particularly with specific agents or in selected high-risk patients, remains clinically relevant. The biological relationship between GLP-1 agonist therapy and optic nerve ischemia remains uncertain
Whilst Wegovy provides pharmacological support for weight loss, optimal outcomes are achieved when combined with reduced calorie intake and increased physical activity
If symptoms continue beyond this timeframe, your doctor may recommend additional testing to assess stomach function
When Retatrutide activates GLP-1 receptors, it slows down digestion, reduces hunger signals in the brain, and helps the body release insulin more effectively
Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomized, open-label, parallel-group, phase 3 trial